Get the Stockscreener App
8.2389
1.61%
-0.1211
Verve Therapeutics Inc stock is traded at $8.2389, with a volume of 521.11K.
It is down -1.61% in the last 24 hours and up +28.12% over the past month.
Verve Therapeutics Inc is a genetic medicines company pioneering a new approach to the care of cardiovascular disease, transforming treatment from chronic management to single-course gene editing medicines. The company's initial two programs target PCSK9 and ANGPTL3, genes that have been extensively validated as targets for lowering blood lipids such as low-density lipoprotein cholesterol, a root cause of cardiovascular disease. The company views its operations as and manages its business in one operating segment operating exclusively in the United States.
See More
Previous Close:
$8.36
Open:
$8.32
24h Volume:
521.11K
Relative Volume:
0.32
Market Cap:
$707.79M
Revenue:
$20.65M
Net Income/Loss:
$-192.65M
P/E Ratio:
-3.181
EPS:
-2.59
Net Cash Flow:
$-134.39M
1W Performance:
+8.08%
1M Performance:
+28.12%
6M Performance:
+44.81%
1Y Performance:
-24.89%
1-Day Range:
$8.06
$8.52
1-Week Range:
$6.9501
$8.77
52-Week Range:
$4.305
$19.34
Verve Therapeutics Inc Stock (VERV) Company Profile
Name
Verve Therapeutics Inc
Sector
Industry
Phone
(978) 501-3026
Address
201 BROOKLINE AVENUE, BOSTON
Compare VERV with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VERV
Verve Therapeutics Inc
|
8.245 | 707.79M | 20.65M | -192.65M | -134.39M | -2.59 |
|
VRTX
Vertex Pharmaceuticals Inc
|
473.66 | 123.91B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
716.52 | 78.94B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
653.67 | 39.98B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
275.46 | 35.89B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
119.25 | 28.75B | 3.30B | -501.07M | 1.03B | -2.1146 |
Verve Therapeutics Inc Stock (VERV) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-08-24 | Initiated | H.C. Wainwright | Buy |
| Apr-13-23 | Initiated | Canaccord Genuity | Buy |
| Feb-01-23 | Initiated | Cantor Fitzgerald | Neutral |
| Dec-15-22 | Initiated | Goldman | Sell |
| Oct-06-22 | Initiated | Credit Suisse | Neutral |
| Aug-25-22 | Upgrade | Stifel | Hold → Buy |
| Jun-17-22 | Initiated | BMO Capital Markets | Outperform |
| Feb-18-22 | Initiated | RBC Capital Mkts | Outperform |
| Sep-24-21 | Initiated | Stifel | Hold |
| Jul-12-21 | Initiated | Guggenheim | Buy |
| Jul-12-21 | Initiated | JP Morgan | Neutral |
| Jul-12-21 | Initiated | Jefferies | Buy |
| Jul-12-21 | Initiated | William Blair | Outperform |
View All
Verve Therapeutics Inc Stock (VERV) Latest News
Buy Rating for Verve Therapeutics: VERVE-102’s Enhanced Safety and Promising Efficacy Boost Investor Confidence - TipRanks
Verve Therapeutics Inc [VERV] stock for 3,130 USD was sold by Dorval Allison - Knox Daily
Perhaps timely catching Verve Therapeutics Inc (VERV) would be a good idea - SETE News
Verve Therapeutics Investor Drops Suit Over Clinical Trial Halt - Bloomberg Law
France Programmatic Ad Seller Quality Rankings Q4 2024: Outbrain Tops Pixalate’s Web Seller Trust Index; Verve No. 1 on Mobile - GlobeNewswire Inc.
STATE STREET CORP Reduces Stake in Verve Therapeutics Inc - GuruFocus.com
Verve Therapeutics' Market Cap Up US$69m Following Year Of Insider Stock Buying - Simply Wall St
Verve Therapeutics (NASDAQ:VERV) Shares Gap UpWhat's Next? - MarketBeat
Is Now The Time To Buy Verve Therapeutics Inc (NASDAQ: VERV) Stock? - Stocks Register
Is Verve Therapeutics Inc (VERV) a threat to investors? - US Post News
Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Verve Therapeutics Awards $1M+ in Equity Incentives to Accelerate Growth Strategy - StockTitan
Verve Therapeutics (NASDAQ:VERV) Trading Down 5.7%Should You Sell? - MarketBeat
Nisa Investment Advisors LLC Raises Stake in Verve Therapeutics, Inc. (NASDAQ:VERV) - MarketBeat
Verve Therapeutics (NASDAQ:VERV) Trading 5.6% HigherHere's Why - MarketBeat
(VERV) Proactive Strategies - Stock Traders Daily
Millennium Management LLC Reduces Stake in Verve Therapeutics Inc - GuruFocus.com
Kuehn Law Encourages Investors of Verve Therapeutics, Inc. to Contact Law Firm - PR Newswire
Verve Therapeutics (NASDAQ:VERV) Trading Down 8.2%What's Next? - MarketBeat
Verve Therapeutics, Inc. (NASDAQ:VERV) Shares Purchased by Nisa Investment Advisors LLC - Defense World
Verve Therapeutics to Participate in the Guggenheim Securities SMID Cap Biotech Conference - GlobeNewswire
Inside Verve's Next Move: CEO Kathiresan Takes Center Stage at Elite Biotech Summit - StockTitan
VERV SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Verve Therapeutics, Inc. Investors Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Companies Like Verve Therapeutics (NASDAQ:VERV) Are In A Position To Invest In Growth - Yahoo Finance
2025-01-26 | Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Verve Therapeutics, Inc. (VERV) and Encourages Shareholders to Learn More About the Investigation | NDAQ:VERV | Press Release - Stockhouse Publishing
Verve Therapeutics (NASDAQ:VERV) Trading Up 6.1%Should You Buy? - MarketBeat
Verve Therapeutics (VERV) Moves 18.7% Higher: Will This Strength Last? - Yahoo Finance
Brokers Offer Predictions for VERV FY2025 Earnings - MarketBeat
Verve Therapeutics (NASDAQ:VERV) Stock Price Up 6.1%Here's Why - MarketBeat
Cantor Fitzgerald Forecasts VERV FY2025 Earnings - MarketBeat
(VERV) Trading Advice - Stock Traders Daily
2025-01-19 | Bronstein, Gewirtz & Grossman, LLC Encourages Verve Therapeutics, Inc. (VERV) Shareholders to Inquire about Securities Investigation | NDAQ:VERV | Press Release - Stockhouse Publishing
Verve Therapeutics (NASDAQ:VERV) Trading 8.6% HigherTime to Buy? - MarketBeat
GAMMA Investing LLC Has $34,000 Holdings in Verve Therapeutics, Inc. (NASDAQ:VERV) - Defense World
JPMorgan Chase & Co. Decreases Stock Holdings in Verve Therapeutics, Inc. (NASDAQ:VERV) - Defense World
Harbor Capital Advisors Inc. Sells 11,980 Shares of Verve Therapeutics, Inc. (NASDAQ:VERV) - Defense World
Verve Therapeutics, Inc. (NASDAQ:VERV) Stake Raised by Barclays PLC - MarketBeat
Verve Therapeutics, Inc. (NASDAQ:VERV) Shares Purchased by Barclays PLC - Defense World
Analysts’ Revisions Show Improving Sentiment For Verve Therapeutics Inc (NASDAQ: VERV) - Stocks Register
Verve Therapeutics Announces Pipeline Progress and Anticipated 2025 Milestones - The Manila Times
Bronstein, Gewirtz & Grossman, LLC Encourages Verve Therapeutics, Inc. (VERV) Stockholders to Inquire about Securities Investigation - AccessWire
Learn to Evaluate (VERV) using the Charts - Stock Traders Daily
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Verve Therapeutics, Inc. (VERV) and Encourages Investors to Learn More About the Investigation - AccessWire
IMTX: 3 Small-Cap Healthcare Stocks With Big Upside Potential - StockNews.com
Verve Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference - The Manila Times
Verve Therapeutics CEO to Present at J.P. Morgan Healthcare Conference 2025 - StockTitan
Verve Therapeutics, Inc. (VERV) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - AccessWire
2025-01-05 | Verve Therapeutics, Inc. (VERV) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation | NDAQ:VERV | Press Release - Stockhouse Publishing
Verve Therapeutics Grants New Employee RSU Awards Under 2024 Inducement Plan - StockTitan
Verve Therapeutics (NASDAQ:VERV) Trading 6.2% HigherWhat's Next? - MarketBeat
Verve Therapeutics Inc Stock (VERV) Financials Data
Revenue
Net Income
Cash Flow
EPS
Verve Therapeutics Inc Stock (VERV) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Kathiresan Sekar | Chief Executive Officer |
Jun 28 '24 |
Option Exercise |
2.87 |
30,000 |
86,100 |
351,128 |
| Ashe Andrew D. | See Remarks |
May 14 '24 |
Buy |
6.26 |
76,000 |
475,760 |
342,509 |
| Nickerson Joan | Chief Administrative Officer |
Apr 02 '24 |
Sale |
8.24 |
1,514 |
12,475 |
8,659 |
0.56%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):